BeyondSpring Inc
BeyondSpring Inc (BYSI) Option Chain
As of September 18, 2026, BeyondSpring Inc is trading at $0.75, a +5.79% change from the previous close. The nearest expiration is Oct 16, 2026. Implied volatility is 424.1%. IV Rank is 84%.
Read more
Tracking the BYSI option chain helps you see every strike and expiry on BeyondSpring Inc in one view, so you can quickly identify the contracts that fit your thesis and your risk. BeyondSpring Inc's option chain lays out bids, asks, volume, open interest, and Greeks across calls and puts, giving you the full map of BYSI options activity at a glance. Use our scanner to monitor the BYSI option chain in real time and filter for the BYSI options trades that actually meet your criteria.
An option chain is the complete listing of all available option contracts on an underlying, organized by expiration date and strike price. For BYSI stock options, the chain shows side-by-side call and put data, making it easy to compare premiums, assess liquidity, and spot pricing dislocations. Reading the BYSI option chain effectively means looking beyond the last price — implied volatility by strike, volume-to-open-interest ratios, and bid-ask spreads all tell you where BYSI stock options are being actively traded and where they are not.
BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immune-modulating microtubule-binding agent that has completed Phase III clinical trials for the prevention of chemotherapy-induced neutropenia; and for treatment of later-stage non-small cell lung cancer. It is also developing Plinabulin in combination with various immuno-oncology agents, including nivolumab, a PD-1 antibody for the treatment of NSCLC; nivolumab and ipilimumab, a CTLA-4 antibody for the treatment of SCLC; and in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers.
In addition, the company engages in the development of three small molecule immune agents in preclinical stages; and a drug development platform. The company was founded in 2010 and is headquartered in New York, New York.
Credit spreads, long calls, iron condors, calendar trades — every strategy starts with the same raw material: a clean, complete option chain. Our scanner pulls BeyondSpring Inc's full chain across every expiry, highlights the most liquid strikes, and lets you screen BYSI options by the metrics that matter, from IV skew to volume surges. Stop scrolling through endless rows of BYSI stock options — let the full option chain come to you, pre-filtered and ready to trade.
Stock Statistics
- IndustryBiotechnology
- SectorHealthcare
- IV percentile74.60% Elevated
- Market cap (M$)31
- 52 weeks high-69.26%
- 52 weeks low31.58%
- Analyst recommendationBuy
2.00 - Target price$1.25
66.67% above the current stock price - Dividend—
- Payout ratio—
- Earnings date2026-11-12
- P/E—
- Future P/E—
- EPS (ttm)-0.16
- EPS growth next 5 years—
As of September 18, 2026
| CALLs | PUTs | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Prob. OTM % | Open Interest | Volume | Extrinsic Value | Intrinsic Value | Bid | Ask | Strike | Moneyness % | Bid | Ask | Intrinsic Value | Extrinsic Value | Volume | Open Interest | Prob. OTM % |
| 95.09 | 713 | 0 | 0.05 | 0.00 | — | 0.05 | 2.50 | +252.11 | 1.55 | 2.05 | 1.75 | 0.05 | 0 | 0 | 4.91 |
| 98.74 | 28 | 0 | 0.05 | 0.00 | — | 0.05 | 5.00 | +604.23 | 3.90 | 4.70 | 4.25 | 0.05 | 0 | 0 | 1.26 |
| 99.51 | 0 | 0 | 0.05 | 0.00 | — | 0.05 | 7.50 | +956.34 | 6.30 | 7.30 | 6.75 | 0.05 | 0 | 0 | 0.49 |
As of September 18, 2026
Scan the full option chain in one place
Browse the full BYSI option chain across every strike and expiration, filter by IV, volume, and open interest, and evaluate your trade without switching tools.
Start your 14-day free trial→